PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)

Breast Cancer Clinical Trial

— PRIMe  

Official title:

PRospective Study to Measure the Impact of MammaPrint on Adjuvant Treatment in Hormone Receptor-positive HER2-negative Breast Cancer Patients (PRIMe)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02269813
• Other study ID #: WSG-PRIMe
• Status: Completed
• Start date: April 1, 2015
• Est. completion date: September 30, 2016

Study information

• Verified date: August 2019
• Source: West German Study Group
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

PRIMe is a prospective, case-only trial designed to measure the impact of MammaPrint on physician chemotherapy intention in the two discordant groups (ET/POOR, CT/GOOD) in stage 1 and 2 HR-positive HER2-negative breast cancer patients. The design also provides for assessment of several important secondary indicators. Eligible patients will have their tumor sample analyzed for MammaPrint, BluePrint and TargetPrint. Patients cannot start treatment before the MammaPrint result is received and taken into consideration for the adjuvant treatment plan.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 452
• Est. completion date: September 30, 2016
• Est. primary completion date: March 31, 2016
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Women with histologically proven invasive stage 1 and 2 breast cancer

• Hormone receptor positive according to local standards

• HER2 negative - i.e. IHC 0-1+, or FISH or other ISH non-amplified (locally assessed)

• Axillary lymph node status: 0-3 involved (macro metastases i.e. >2mm OR micro metastases i.e. >0.2-2mm)

• = 18 years of age at time of consent

• Patients must be eligible to receive adjuvant chemotherapy and endocrine therapy as defined by a good Karnofsky index, no hematological, cardiological or hepatic contraindications nor any impeding comorbidity

• Written informed consent

Exclusion Criteria:

• =4 involved axillary nodes

• Multi-centric disease with more than 2 clinically relevant lesions

• HR negative OR HER2 positive/amplified (locally assessed)

• Previous diagnosis of malignancy unless disease free for 10 years

• Metastatic disease

• Tumor sample shipped to Agendia with = 30% tumor cells or that fails QA or QC criteria

• Women who have started or completed adjuvant chemotherapy or neo-adjuvant chemotherapy for current breast cancer

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Other:
• MammaPrint

• BluePrint

• TargetPrint

Locations

Country	Name	City	State
Austria	Medizinische Universität Innsbruck Universitätsklinik für Frauenheilkunde	Innsbruck
Germany	Breast Center of the University of Munich (LMU)	Munich
Switzerland	Kantonsspital St.Gallen	St. Gallen

Sponsors (2)

Lead Sponsor	Collaborator
West German Study Group	Agendia

Countries where clinical trial is conducted

Austria,  Germany,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure the impact of MammaPrint on adjuvant treatment decisions in discordant groups (ET/POOR and CT/GOOD) in stage-1/2, HR+, HER2- breast cancer and test whether these impacts each exceed a pre-determined compliance threshold.	Compliance, assessed in terms of the fraction of patients in each discordant group whose physicians switch their chemotherapy intention following MammaPrint test disclosure is used to measure the impact of MammaPrint on adjuvant treatment decisions.	Up to 6 months after end of treatment.
Primary	Assess the incremental cost-effectiveness of MammaPrint in terms of cost and quality-adjusted life years within a health economic context using the impacts measured in this trial as well as the predictive impact demonstrated in previous trials.		Up to 6 months after end of treatment.
Secondary	Measure the impacts of MammaPrint on adjuvant treatment decisions (physician chemotherapy intention) and compare with previous trials involving MammaPrint or other tests.	The planned analysis includes assessment of the incremental cost-effectiveness (ICER) of MammaPrint within a health economic context (i.e., taking cost and quality-adjusted life years into account).	Up to 6 months after end of treatment.
Secondary	Measure rate (by incidence) and severity (by Common Toxicity Criteria) of treatment-related serious adverse events stratified by whether or not patient received adjuvant chemotherapy.		Up to 6 months after end of treatment.
Secondary	Assess change in patients' decisional conflict status and anxiety levels before and after MammaPrint results via questionnaire, stratified by the four groups (2 concordant and 2 discordant).		Up to 6 months after end of treatment.
Secondary	Assess investigators' confidence in treatment recommendations before and after MammaPrint results were known via questionnaire.		Up to 6 months after end of treatment.
Secondary	Assess concordance of final treatment intention and treatment actually received by number of patients.		Up to 6 months after end of treatment.
Secondary	Assess concordance of TargetPrint ER, PR and HER2 results with locally assessed IHC/FISH ER, PR and HER2 by number of patients.		Up to 6 months after end of treatment.
Secondary	Compare clinical subtype based on IHC/FISH ER, PR, HER2 and Ki-67 (St Gallen 2013) with BluePrint molecular subtype by diagnostic definition of subtype.		Up to 6 months after end of treatment.
Secondary	Assess concordance of MammaPrint, BluePrint and TargetPrint in multi-centric breast cancer by number of patients.		Up to 6 months after end of treatment.
Secondary	Assess the combined switch rate in the two concordant groups (ET/GOOD) and (CT/POOR) and verify that it is lower than the switch rate in both discordant groups by number of patients.		Up to 6 months after end of treatment.
Secondary	Perform descriptive sub-analysis in pre- and post-menopausal women by switch percentages.		Up to 6 months after end of treatment.
Secondary	Perform cross-validation with other adjuvant breast cancer studies by switch rate, if available.		Up to 6 months after end of treatment.